Childhood neuroblastoma is the most common cancer that occurs in infancy. The MYCN oncogene has been shown to be a strong indicator for this cancer. MYCN is a transcription factor that requires the expression of MAX to exert its function.
In this new study, researchers illustrate that the MAX to MYCN ratio accounts for tumour progression and clinical outcome in neuroblastoma and proposes that such a ratio should be considered as an important criterion to the design and development of anti-MYCN therapies. Chromatin immunoprecipitation was used for transcription factor study and the Bioruptor Pico was key to shearing chromatin for this study.